Lyell Immunopharma co-led a series A round for the gene therapy developer, which was spun off by the corporate's co-founders.
US-based smart cell therapy developer Outpace Bio completed a $30m series A round yesterday co-led by cellular therapy developer Lyell Immunopharma and venture capital firm Artis Ventures.
Abstract Ventures, Civilization Ventures, Mubadala Capital, Playground Global, Sahsen Ventures and WRF Capital also took part in the round. The company has not revealed any details of seed financing.
Outpace is working on synthetic proteins using its own biological software and hardware, and is initially focusing on ultra-specific T cell therapies for solid…
